| abstract |
According to the invention, the compound of formula (I) [Wherein Q is By and; A is a hydrogen atom, a halogen atom, -ORa, or one or more optionally substituted C 1-4 alkyl group by a halogen atom,; E is independently from C 1-6 alkyl group M is selected from an integer from 0 to 3; R 2 and R 3 are independently selected from a C 1-6 alkyl group; X 1 and X 2 are independently selected from O and S Y is selected from an arylene group and a divalent 5- or 6-membered monocyclic or 8- to 10-membered fused heterocyclic group; Z is -CON (-Ra)-, -CO-,- COO—, —NRa—C (═NH) NRb—, —NRa— (C═N—CN) NRb—, —N (—Ra) COO—, —C (═NH) —, —SO 2 —, — SO 2 N (-Ra) -, - SO 2 NR 1 -, - N (-Ra) CO -, - N (-Ra CON (-Rb) -, - N (COR 1) CO -, - N (-Ra) SO 2 -, - N (SO 2 R 1) SO 2 -, - N (-Ra) -, or -N ( -Ra) SO 2 N (-Rb) - a is compound represented by, a salt, a prodrug or a solvate thereof is provided. Furthermore, a pharmaceutical composition containing the compound or the like is also provided. |